全文获取类型
收费全文 | 6000篇 |
免费 | 269篇 |
国内免费 | 102篇 |
专业分类
耳鼻咽喉 | 63篇 |
儿科学 | 71篇 |
妇产科学 | 172篇 |
基础医学 | 442篇 |
口腔科学 | 198篇 |
临床医学 | 440篇 |
内科学 | 1998篇 |
皮肤病学 | 84篇 |
神经病学 | 401篇 |
特种医学 | 219篇 |
外科学 | 1302篇 |
综合类 | 27篇 |
现状与发展 | 1篇 |
一般理论 | 2篇 |
预防医学 | 220篇 |
眼科学 | 131篇 |
药学 | 238篇 |
中国医学 | 3篇 |
肿瘤学 | 359篇 |
出版年
2024年 | 6篇 |
2023年 | 70篇 |
2022年 | 150篇 |
2021年 | 276篇 |
2020年 | 163篇 |
2019年 | 218篇 |
2018年 | 263篇 |
2017年 | 155篇 |
2016年 | 191篇 |
2015年 | 178篇 |
2014年 | 292篇 |
2013年 | 337篇 |
2012年 | 509篇 |
2011年 | 547篇 |
2010年 | 350篇 |
2009年 | 311篇 |
2008年 | 442篇 |
2007年 | 465篇 |
2006年 | 427篇 |
2005年 | 310篇 |
2004年 | 258篇 |
2003年 | 179篇 |
2002年 | 143篇 |
2001年 | 31篇 |
2000年 | 7篇 |
1999年 | 12篇 |
1998年 | 25篇 |
1997年 | 13篇 |
1996年 | 8篇 |
1995年 | 7篇 |
1994年 | 14篇 |
1993年 | 2篇 |
1992年 | 3篇 |
1991年 | 1篇 |
1990年 | 1篇 |
1989年 | 1篇 |
1984年 | 2篇 |
1979年 | 1篇 |
1975年 | 2篇 |
1969年 | 1篇 |
排序方式: 共有6371条查询结果,搜索用时 15 毫秒
121.
Maria Drakopoulou George Oikonomou Stergios Soulaidopoulos Basil Thanopoulos Konstantina Aggeli Dimitrios Tousoulis Konstantinos Toutouzas 《Congenital heart disease》2020,15(3):147-151
The percutaneous closure of ostium secundum atrial septal defects
(ASD) is a well-established procedure. Currently available devices and delivery
systems are designed to be used via the femoral venous route. However, an
alternative approach needs to be considered in cases of congenital or acquired
caval obstruction. We describe a successful transjugular closure of a moderate
sized secundum ASD with the Cocoon Septal Occluder in a 37-year-old
symptomatic woman with inferior vena cava (IVC) thrombosis, using a novel
deployment technique to overcome difficulties, namely maintaining stable sheath
position in the left atrium. Percutaneous closure of secundum ASDs via the
transjugular approach is safe, feasible and effective and can be a reasonable
alternative to surgical closure in patients with failed femoral venous access and
not anatomically complex atrial septal defects. 相似文献
122.
123.
Eleni Koraki Ioannis Mantzoros Christos Chatzakis Anna Gkiouliava Angeliki Cheva Athina Lavrentieva Freideriki Sifaki Helena Argiriadou Isaak Kesisoglou Konstantinos Galanos-Demiris Stefanos Bitsianis Konstantinos Tsalis 《World journal of hepatology》2020,12(11):1098-1114
BACKGROUNDHepatectomy with inflow occlusion results in ischemia-reperfusion injury; however, pharmacological preconditioning can prevent such injury and optimize the postoperative recovery of hepatectomized patients. The normal inflammatory response after a hepatectomy involves increased expression of metalloproteinases, which may signal pathologic hepatic tissue reformation. AIMTo investigate the effect of desflurane preconditioning on these inflammatory indices in patients with inflow occlusion undergoing hepatectomy.METHODSThis is a single-center, prospective, randomized controlled trial conducted at the 4th Department of Surgery of the Medical School of Aristotle University of Thessaloniki, between August 2016 and December 2017. Forty-six patients were randomized to either the desflurane treatment group for pharmacological preconditioning (by replacement of propofol with desflurane, administered 30 min before induction of ischemia) or the control group for standard intravenous propofol. The primary endpoint of expression levels of matrix metalloproteinases and their inhibitors was determined preoperatively and at 30 min posthepatic reperfusion. The secondary endpoints of neutrophil infiltration, coagulation profile, activity of antithrombin III (AT III), protein C (PC), protein S and biochemical markers of liver function were determined for 5 d postoperatively and compared between the groups.RESULTSThe desflurane treatment group showed significantly increased levels of tissue inhibitor of metalloproteinases 1 and 2, significantly decreased levels of matrix metalloproteinases 2 and 9, decreased neutrophil infiltration, and less profound changes in the coagulation profile. During the 5-d postoperative period, all patients showed significantly decreased activity of AT III, PC and protein S (vs baseline values, P < 0.05). The activity of AT III and PC differed significantly between the two groups from postoperative day 1 to postoperative day 5 (P < 0.05), showing a moderate drop in activity of AT III and PC in the desflurane treatment group and a dramatic drop in the control group. Compared to the control group, the desflurane treatment group also had significantly lower international normalized ratio values on all postoperative days (P < 0.005) and lower serum glutamic oxaloacetic transaminase and serum glutamic pyruvic transaminase values on postoperative days 2 and 3 (P < 0.05). Total length of stay was significantly less in the desflurane group (P = 0.009).CONCLUSIONDesflurane preconditioning can lessen the inflammatory response related to ischemia-reperfusion injury and may shorten length of hospitalization. 相似文献
124.
125.
126.
127.
128.
Konstantinos Tselios Charalampos Koumaras Murray B. Urowitz Dafna D. Gladman 《Seminars in arthritis and rheumatism》2014
Objective
Arterial hypertension (HTN) is reported to burden up to 74% of systemic lupus erythematosus (SLE) patients and contributes significantly to accelerated atherosclerosis and increased cardiovascular (CV) risk. Current HTN treatment guidelines have not incorporated lupus patients in their recommendations; whether these guidelines can be fully implemented in SLE is doubtful.Methods
A critical appraisal of the existing HTN guidelines in regard to SLE is presented in this review, based upon clinical and experimental data. Particular issues addressed are the time of antihypertensive therapy initiation, the optimal blood pressure level, the antihypertensive agent of first-choice and the need for reduction of the total cardiovascular risk in SLE.Results
Antihypertensive therapy should be recommended at levels of 140/90 mmHg (systolic and diastolic BP, respectively) in newly diagnosed lupus patients without overt target organ involvement. In the case of lupus nephritis (LN) or diabetes mellitus (DM), therapy should be implemented at lower levels, such as 130/80 mmHg. Hypertensive lupus patients should be considered at high or very high CV risk and, consequently, the optimal BP level should be less than 130/80 mmHg. Angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) seem to be a safe and efficacious first-choice antihypertensive treatment in lupus patients. Total CV risk should be considered and co-morbidities (dyslipidemia, antiphospholipid syndrome, etc.) should be managed promptly.Conclusions
Current HTN therapeutic guidelines, lacking data from large-scale clinical trials, may not adequately apply to SLE patients. The assessment of the aforementioned recommendations in randomized clinical trials is expected to confirm their value in reducing CV risk in SLE. 相似文献129.
Rachael O. Forsythe Jan Apelqvist Edward J. Boyko Robert Fitridge Joon Pio Hong Konstantinos Katsanos Joseph L. Mills Sigrid Nikol Jim Reekers Maarit Venermo R. Eugene Zierler Nicolaas C. Schaper Robert J. Hinchliffe 《Diabetes/metabolism research and reviews》2020,36(Z1)
The accurate identification of peripheral artery disease (PAD) in patients with diabetes and foot ulceration is important, in order to inform timely management and to plan intervention including revascularisation. A variety of non‐invasive tests are available to diagnose PAD at the bedside, but there is no consensus as to the most useful test, or the accuracy of these bedside investigations when compared to reference imaging tests such as magnetic resonance angiography, computed tomography angiography, digital subtraction angiography or colour duplex ultrasound. Members of the International Working Group of the Diabetic Foot updated our previous systematic review, to include all eligible studies published between 1980 and 2018. Some 15 380 titles were screened, resulting in 15 eligible studies (comprising 1563 patients, of which >80% in each study had diabetes) that evaluated an index bedside test for PAD against a reference imaging test. The primary endpoints were positive likelihood ratio (PLR) and negative likelihood ratio (NLR). We found that the most commonly evaluated test parameter was ankle brachial index (ABI) <0.9, which may be useful to suggest the presence of PAD (PLR 6.5) but an ABI value between 0.9 and 1.3 does not rule out PAD (NLR 0.31). A toe brachial index >0.75 makes the diagnosis of PAD less likely (NLR 0.14‐0.24), whereas pulse oximetry may be used to suggest the presence of PAD (if toe saturation < 2% lower than finger saturation; PLR 17.23‐30) or render PAD less likely (NLR 0.2‐0.27). We found that the presence of triphasic tibial waveforms has the best performance value for excluding a diagnosis of PAD (NLR 0.09‐0.28), but was evaluated in only two studies. In addition, we found that beside clinical examination (including palpation of foot pulses) cannot reliably exclude PAD (NLR 0.75), as evaluated in one study. Overall, the quality of data is generally poor and there is insufficient evidence to recommend one bedside test over another. While there have been six additional publications in the last 4 years that met our inclusion criteria, more robust evidence is required to achieve consensus on the most useful non‐invasive bedside test to diagnose PAD. 相似文献
130.
Anastasios Kollias Konstantinos G. Kyriakoulis George S. Stergiou 《Journal of clinical hypertension (Greenwich, Conn.)》2020,22(5):929-932
There is disagreement between the American and the European guidelines for hypertension management in regard to the optimal blood pressure target in patients with chronic kidney disease (CKD). Randomized clinical trials and meta‐analyses of individual patient data pooled from these trials do not clearly support an intensive blood pressure target for the entire population of CKD patients with hypertension. However, some evidence suggests that in CKD patients with proteinuria strict blood pressure control might confer benefit in terms of renal outcome. Tailored treatment strategy based on the individual’s proteinuric profile and tolerability along with standardization of blood pressure measurement methodology including out‐of‐office evaluation are of paramount importance in patients with CKD. 相似文献